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Osteoarthritis currently has no cure. Acupuncture can beneﬁt patients with knee osteoarthritis by providing pain relief, improving
joint function and serving as an eﬀective complement to standard care. However, the underlying mechanisms of its eﬀects are still
not completely understood. The present study, an investigation of the eﬀectiveness and mechanisms of electroacupuncture (EA) in
attenuating osteoarthritis pain in a rat model, is focused on the involvement of 5-hydroxytryptamine 2A/C (5-HT2A/C) receptors,
which play an important role in pain modulation at the spinal level. Osteoarthritis was induced under isoﬂurane anesthesia by a
singleintraarticularinjectionofmonosodiumiodoacetate(3mg/50μL/rat)intoonehindlegofeachrat.EAwasgivenatacupoints
GB30andST36ondays1–4aftertheinjection.Vehicleorketanserin,a5-HT2A/Creceptorantagonist,wasgivenintraperitoneally
(1mgkg−1)o ri n t r a t h e c a l l y( 5 μgo r1 0 μg/10μL), 30min before each EA treatment. Assessment of weight-bearing diﬀerence
between injected and uninjected hind legs was done on days 0, 1–4 and 7. Fos /serotonin and serotonin/Fluorogold double labeling
were performed to determine EA activation of serotonergic neurons in the nucleus raphe magnus (NRM) that project to spinal
cord. The results showed that EA signiﬁcantly decreases weight-bearing diﬀerence compared to sham EA. Ketanserin pretreatment
blocked the analgesic eﬀect of EA but did not inﬂuence weight bearing in sham EA control rats. EA also activated serotonergic
NRM neurons that project to the spinal cord. These data show that EA inhibits osteoarthritis-induced pain by enhancing spinal
5-HT2A/2C receptor activity.
1.Introduction
Osteoarthritis, a widespread condition, aﬀects nearly 21
million people in the United States. Its prevalence after age
65 is about 60% in men and 70% in women [1]. Its main
symptom is chronic pain that causes loss of mobility and
often stiﬀness.
Osteoarthritis is irreversible, and currently there is no
cure. The purpose of pharmacological treatments is to
control pain and reduce functional limitation. Frequently
used medications such as non-steroidal anti-inﬂammatory
drugs have serious and even dangerous side eﬀects, including
bleeding and perforated ulcers [2, 3]. Cyclooxygenase-2
inhibitors can reduce the gastrointestinal side eﬀects, but
these carry an elevated risk for cardiovascular disease, and
some have now been withdrawn from the market [4].
Thus, more and more patients turn to complementary and
alternative therapies.
Acupuncture, a commonly used complementary therapy
with few or no adverse eﬀects, has been used in China for
thousands of years to treat a variety of conditions, including
pain. Its popularity in western countries has been increasing
in recent years. There are reports that acupuncture can
beneﬁt patients with knee osteoarthritis by providing pain
relief, improving joint function and serving as an eﬀective
complement to standard care [5–8]. However, its underlying
mechanisms are still not completely understood.
In the central nervous system, there are several 5-
HT receptor subtypes, of which both 5-HT2A and 5-
HT2C are important in the perception of pain. It has
been reported that m-5-HT, a 5-HT2A/2C receptor agonist,
dosage-dependently suppressed the number of ﬂinches in
the formalin test and attenuated thermal hyperalgesia in
a chronic constriction injury model. These eﬀects were
reversed by a 5-HT2A/2C antagonist, ketanserin, which
blocks the 5-HT2A and 5-HT2C receptors [9]. The data2 Evidence-Based Complementary and Alternative Medicine
demonstrate that these receptors play a key role in persistent
pain.
The aims of the present study were to test whether
electroacupuncture (EA) eﬀectively attenuates pain in an
osteoarthritis rat model and whether 5-HT2A/C receptors
are involved in such attenuation. Serotonin, an important
neurotransmitter, modulates the transmission of noxious
messages at the spinal level [10]. Intrathecally (i.t.) admin-
istered, it produces anti-nociception in rats, rabbits and cats
[11]. Since serotonin neurons in the NRM participate in
pain modulation [10], we also double labeled serotonin and
Fluorogold, a retrograde tracer, which was injected into the
spinal cord, and serotonin and Fos, an indicator of neuron
activation, to determine whether EA activates serotonergic
NRM neurons that project to the spinal cord.
2. Methods
2.1. Animal Preparation. Male Sprague-Dawley rats weigh-
ing 280–350g (Harlan, Indianapolis, IN) were kept under
controlled environmental conditions (22◦C, relative humid-
ity 40%–60%, 12-h alternate light-dark cycles, food and
water ad libitum). The animal protocols were approved by
the Institutional Animal Care and Use Committee of the
University of Maryland School of Medicine.
2.2. Experimental Design. Osteoarthritis was induced in all
rats by a single intra-articular injection of monosodium
iodoacetate(Sigma)dissolvedinsaline[12].Brieﬂy,ratswere
anesthetized with isoﬂurane, and monosodium iodoacetate
(3mg/50μL/rat) was injected into the left knee joint cavity
usinga29-gaugeneedleinsertedthroughthepatellartendon.
To set up the osteoarthritis rat model in our lab, two
groups of rats (n = 8 per group) were used in the ﬁrst
experiment: one received monosodium iodoacetate and the
other received saline. Hind limb weight-bearing diﬀerences
were assessed on days 0, 1–4 and 7 after the intra-articular
injection. To investigate EA inhibition of pain in the arthritis
rat model and the participation of 5HT2A/2C receptors
in this eﬀect, the monosodium iodoacetate-injected rats
received intraperitoneal (i.p.) ketanserin or vehicle and were
randomly divided into four groups (n = 8p e rg r o u p ) :E A
plus ketanserin (1mgkg−1, i.p.) dissolved in 10% DMSO,
EA plus vehicle (10% DMSO in saline), sham EA plus
ketanserin and sham EA plus vehicle. To specify whether an
5HT2A/2C antagonist acted in the spinal cord, another set
ofmonosodiumiodoacetate-injectedratsreceivedketanserin
or vehicle and were randomly divided into EA plus
ketanserin (10μg/10μL, i.t.), EA plus ketanserin (5μg/10μL,
i.t.)orEAplusvehicle(i.t.)groups.EAwasgivenondays1–4
30min after the drug or vehicle injection. Behavioral tests to
assess pain were given on day 0 for baseline, day 1 before EA
treatment to conﬁrm the development of arthritis pain, days
2–4 17h post-EA to determine the eﬀect of EA on arthritis
pain and day 7 to observe long-term eﬀects. It should be
noted that we performed behavioral tests on the day after EA
treatment to rule out any eﬀect from the isoﬂurane.
Another six rats were used in an immunoﬂuorescence
study.ThreeweretreatedoncewithEAandperfused2hlater.
Their brainstems were removed and double labeled for Fos
and serotonin. The spinal cords of other three were injected
with Fluorogold, and Fluorogold and serotonin were double
labeled in the NRM.
2.3. Pain Assessment. Pain-related behaviors were assessed
using a hind limb weight-bearing apparatus (Model-600,
IITC Life Science). Rats were allowed to acclimate to
the testing apparatus for 30min a day, 2-3 days before
experiment. The amount of weight supported by each hind
leg was measured automatically and separately every 5 s.
At each time point, ﬁve readings were taken for each rat
and averaged ﬁrst for each individual and then for the
group. Weight-bearing diﬀerence between the two legs was
presented as the percentage of weight borne by the ipsilateral
leg and was determined using the following formula: %
weight on the ipsilateral leg = weight on the ipsilateral leg/
(weight on the contralateral leg + weight on the ipsilateral
leg) ×100%.
2.4. Acupuncture Treatment Procedures. A 30-min EA treat-
ment was given once a day on days 1–4 after the iodoacetate
injection. EA parameters of 10Hz at 2mA and 0.4 ms pulse
width, which showed signiﬁcant antihyperalgesic eﬀects on a
bonecancerpainratmodelinourpreviousstudies[13],were
used. The equivalents of human acupoints Huantiao (GB30)
and Zusanli (ST 36) were chosen for bilateral needling based
on traditional Chinese medicine meridian theory [14]. In
humans, GB30 is located at the junction of the lateral 1/3
andmedial2/3ofthedistancebetweenthegreatertrochanter
and the hiatus of the sacrum; underneath are the sciatic
nerve, inferior gluteal nerve and gluteal muscles [15]. ST 36
is located on the anterior aspect of the lower leg, 3U (based
on the standard acupuncture measurement of 16U between
the knee and the ankle joint) below the knee joint and one
ﬁnger-breadth (middle ﬁnger) lateral to the anterior crest
of the tibia. The anatomical structure of this point involves
the tibialis anterior muscle; underneath is the deep peroneal
nerve. These acupoints were located on the rat’s hind limbs
using the comparable anatomical landmarks.
The animals were gently handled for 30min each day
for 2-3 days and habituated to the handling and experi-
mental environment. After cleaning with alcohol swabs and
anesthetizing with isoﬂurane using a Vaporizer (Harvard
Apparatus), two disposable acupuncture needles (gauge #32,
0.5 inch in length) were inserted ∼0.5 inch into GB 30
and 0.25 inch into ST 36 on the animal’s hind limbs. On
each leg, a pair of electrodes was attached to the ends of
the needles. EA stimulation was delivered by a stimulator
(Electrostimulator 8-C, Pantheon Research Inc.) at 10Hz,
2mA and 0.4ms pulse width for 30min on days 1–4. While
frequency was held constant, intensity was adjusted slowly
to the designated level of 2mA. Mild muscle twitching
was observed. A symmetrical biphasic wave was delivered
to the electrodes on each leg so that the electrode was
alternately positive and negative, and GB 30 and ST 36 wereEvidence-Based Complementary and Alternative Medicine 3
stimulated alternately. Because the rats were anesthetized
during acupuncture treatment, they were not restrained.
For sham treatment control, acupuncture needles were
inserted bilaterally into GB 30 and ST 36 without electrical
stimulationormanualmanipulation.Thisprocedureiscom-
parable to actual treatment but produces little therapeutic
eﬀect: our previous study showed that needles inserted
into active acupoints, but given no electrical or manual
stimulation, do not produce analgesia [16].
2.5. Intrathecal Drug Delivery. Acute lumbar punctures were
performedaspreviouslydescribed[17].APE10polyethylene
tube (Clay Adams) was submerged in 70◦Cw a t e r ,s t r e t c h e d
to about 150% of the original length to reduce its diameter
and used as an injection catheter. With a 29-gauge needle,
another 10-cm PE10 tube was connected to one end of
the catheter and then to a 50-μL glass Hamilton syringe
with a PE50 tube. The injection catheter was pre-ﬁlled with
10μLo fd r u go rv e h i c l ea n d5 μL of saline separated by
a small air bubble. Under isoﬂurane anesthesia, the dorsal
pelvic area was shaved and swabbed with 70% alcohol. A
21-gauge sterile needle with the plastic hub removed was
inserted between lumbar vertebrae L5 and L6. The catheter
was inserted into the guide needle and rostrally advanced
4cm from the tip of the needle into the lumber enlargement,
where its arrival was conﬁrmed by a tail-ﬂick. The drug, or
vehicle, was injected and followed by a saline ﬂush. 5min
after injection, the catheter was withdrawn and the needle
was removed from the intervertebral space.
2.6. Immunoﬂuorescence. Rats were deeply anesthetized with
sodium pentobarbital (80mgkg−1, i.p.) and perfused tran-
scardially with 100mL of saline followed by 500mL of 4%
paraformaldehyde in 0.1M phosphate buﬀer at pH 7.4. The
brain stem was removed, immersed in the same ﬁxative
for 2h and transferred to a solution of 30% sucrose in a
phosphate buﬀer for 72h. 40-μm-thick sections were cut
with a cryostat at –20◦C .T h es e c t i o n sw e r ep r o c e s s e dw i t ha
free-ﬂoating stain method. For double immunoﬂuorescence
labeling, brain stem sections were blocked in PBS with 10%
normal donkey serum for 60min and incubated overnight
at room temperature in a mixture of rabbit anti-Fos
(Oncogene, 1:1000) and goat anti-serotonin (ImmunoStar,
1:250). After three 10-min washings in PBS, sections were
incubated in a mixture of CY2-conjugated donkey anti-
rabbit (1:50, Jackson ImmunoResearch Laboratories) and
CY3-conjugated donkey anti-goat (1:200) for 1h at room
temperature. Control sections were similarly processed,
except that the primary antisera were omitted. The stained
sections were mounted on gelatin-coated slides, coverslipped
with aqueous mounting medium (Biomeda Corp., CA,
USA)andexaminedunderaNikonﬂuorescencemicroscope.
Control sections without primary antiserum showed no
immunoreactive staining.
For serotonin and Fluorogold double labeling, Fluoro-
gold (4%, 0.2μL) was injected into the lumbar spinal cord
after a laminectomy under anesthesia with pentobarbital
sodium (50mgkg−1, i.p.). Four days later, the rats were
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Figure 1: Eﬀect of a unilateral intra-articular injection of
monosodium iodoacetate (3mg/50μL/rat) on the weight-bearing
ability of hind legs (n = 8). Note that iodoacetate-injected rats bore
signiﬁcantly less weight on the ipsilateral hind limb than did saline-
injected rats. Abscissas: the time points from the 1st to the 7th
day after iodoacetate; ordinate: body weight diﬀerence. ∗∗∗P < .001
versus saline.
perfused as above. The brain stem sections were incubated
in a mixture of rabbit anti-Fluorogold (Chemicon, 1:1000)
and goat anti-serotonin (ImmunoStar, 1:250). After three
10-min washings in PBS, sections were incubated in a
mixture of CY2-conjugated donkey anti-rabbit (1:50) and
CY3-conjugated donkey anti-goat (1:200) for 1h at room
temperature and then treated as above.
2.7. Data Analysis. Hind limb weight-bearing diﬀerences
were presented as percentage changes and analyzed using
analysis of variance with repeated measures followed by
the post hoc Multiple Comparisons Test (Statistical Analysis
System). P < .05 was set as the level of statistical signiﬁcance.
3. Results
3.1. An Intra-Articular Injection of Iodoacetate Decreased
Weight-Bearing Ability. Before iodoacetate was injected into
the knee joint cavity, there was no signiﬁcant diﬀerence
between right and left hind limb weight bearing in the
groups. After an iodoacetate injection, the ipsilateral hind
limb bore signiﬁcantly (P < .001) less weight than did
salineinjectedlegs(Figure 1),suggestingthattheiodoacetate
induced ipsilateral pain.
3.2. Systemic Ketanserin Prevented EA Restoration of Weight-
Bearing Ability in the Iodoacetate-Injected Knee. As shown in
Figure 2, EA treatment (EA + vehicle) signiﬁcantly restored
theweight-bearingabilityoftheipsilaterallegondays3(41.6
± 2.9 versus 24.3 ± 3.4, P < .01), 4 (41.8 ± 2.1 versus 20.6
± 3.7, P < .001) and 7 (44.6 ± 1.5 versus 30.2 ± 2.8, P <
.05) after the iodoacetate injection compared to sham EA4 Evidence-Based Complementary and Alternative Medicine
&
1d 2d 3d 4d 7d Baseline
15
20
25
30
35
40
45
50
55
EA + vehicle Sham + vehicle
# ∗∗ ∗∗∗
∗
B
o
d
y
b
e
a
r
i
n
g
d
i
ﬀ
e
r
e
n
c
e

w
e
i
g
h
t
o
n
t
h
e
i
p
s
i
l
e
g
s
u
m
o
f
w
e
i
g
h
t
o
n
t
h
e
b
o
t
h
l
e
g
s

×
1
0
0
%
EA
Time after iodoacetate
EA + ketanserin Sham + ketanserin
Figure 2: Eﬀect of EA and a systemic injection of ketanserin on
weightbearinginratswithosteoarthritis.EAsigniﬁcantlydecreased
weight-bearing diﬀerences compared to sham EA on days 3–7 after
iodoacetate. Ketanserin pretreatment blocked the analgesic eﬀect of
EA but did not inﬂuence weight bearing in sham EA control rats.
∗P < .05, ∗∗P < .01, ∗∗∗P < .001 versus sham + vehicle; #P < .01, &P
< .05 versus EA + ketanserin.
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Figure 3: Eﬀect of an i.t. ketanserin injection on EA analgesia.
Ketanserin at 10μg pretreatment signiﬁcantly blocked the analgesic
eﬀect of EA on days 2–7 after iodoacetate. There is no signiﬁcant
diﬀerence between the 5μg and vehicle groups. ∗P < .05, ∗∗P < .01,
∗∗∗P < .001 versus vehicle control.
control(shamEA +vehicle). This indicates that EAinhibited
the iodoacetate-induced pain. Comparison between EA +
ketanserin (i.p.) and EA + vehicle (i.p.) indicates that
ketanserin blocked EA inhibition of the iodoacetate-induced
pain on days 3 (25.84 ± 3.7 versus 41.6 ± 2.9, P < .01) and 4
(28.0 ± 4.3 versus 41.8 ± 2.1, P < .05). Ketanserin treatment
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Figure 4: Co-localization of Fos and 5-HT in the nucleus
raphe magnus. (a) The 5-HT-immunoreactive neurons; (b) Fos-
immunoreactive proﬁles; (c) Merged graphs of (a) and (b). Arrows
indicate double-labeled 5-HT/Fos neurons (yellow). Arrow heads
point to single-labeled neurons.
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Figure 5: Representative photograph showing the co-localization
of serotonin and Fluorogold in the nucleus raphe magnus. (a) The
5-HT-immunoreactive neurons; (b) Fluorogold-labeled neurons
projecting to the spinal cord; (c) Merged graphs of (a) and (b).
Arrowsindicatedouble-labeled5-HT/Fluorogoldneurons(yellow).
plus sham EA produced the same weight-bearing diﬀerence
as that produced by vehicle plus sham EA, suggesting that
ketanserin alone did not inﬂuence the pain.
3.3. Ketanserin Blocked EA Alleviation of the Weight-Bearing
Decrease. As shown in Figure 3,r a t sg i v e nE Ap l u s1 0μgo f
i.t. ketanserin put signiﬁcantly less weight on the ipsilateral
leg than did rats with EA plus vehicle on days 2 (23.5 ± 2.7
versus 38.1 ± 2.5, P < .01), 3 (18.9 ± 1.4 versus 37.3 ± 3.9
versus, P < .001), 4 (22.5 ± 3.1 versus 38.8 ± 2.8, P < .01)
and 7 (32.9 ± 3.6 versus 44.6 ± 1.8, P < .05). Weight bearing
wasnotsigniﬁcantlydiﬀerentbetweenratsgivenEAplus5μg
of ketanserin and those given EA plus vehicle, although the
former showed a slightly greater ability to bear weight. This
indicates that EA may inhibit pain by inducing serotonin
release in the spinal cord.
3.4. EA-Activated Serotonin-Containing NRM Neurons that
Project to the Spinal Cord. Immunoﬂuorescence double
staining of serotonin and Fos demonstrated that EA induced
Fos expression in the NRM (Figure 4(b)). Most EA-induced
Fos was co-localized with serotonin (Figure 4(c)), which
indicates that EA activated serotonergic neurons in this
nucleus. Double staining of serotonin and the retrogradeEvidence-Based Complementary and Alternative Medicine 5
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Figure 6: A schematic illustration of the mechanisms of EA inhibition of pain.
tracer Fluorogold, which was injected into the lumbar spinal
cord, demonstrated that about 50% of NRM neurons that
project to the spinal cord contained serotonin (Figures 5(a)–
5(c)).
4. Discussion
Inthepresentstudy,EAtreatmentsigniﬁcantlydecreasedthe
weight-bearing diﬀerence between healthy and inoculated
hind legs when compared to sham EA in the iodoacetate-
induced osteoarthritis rat model. This suggests that EA
treatment signiﬁcantly relieves spontaneous pain in this
model. The data are consistent with a previous report that
EA signiﬁcantly improved weight-bearing force in an animal
modelofarthriticpaininducedbyinjectingcarrageenaninto
the knee joint cavity [18]. Clinical trials have also reported
that, compared to control, EA signiﬁcantly improved pain
and joint function as assessed with the Western Ontario
and McMaster Universities’ Osteoarthritis Index in patients
withkneeosteoarthritisduringalong-termfollow-upperiod
of 8–26 weeks [6, 7]. These basic and clinical studies
demonstrate that acupuncture can beneﬁt osteoarthritis
patients.
Moreover, our study showed that ketanserin, a selective
5-HT2A/C receptor antagonist, produced no signiﬁcant
eﬀect in sham EA control osteoarthritis rats. This suggests
thattheshamEAdidnotactivatetheserotoninsystem.How-
ever,theanalgesiceﬀectofEAontheosteoarthritisratmodel
was blocked by systemic ketanserin (Figure 2), indicating
that EA treatment induced the release of serotonin, which
activated 5-HT2A/2C receptors to alleviate pain. Further,
i.t. ketanserin at 10μg, but not 5μg, signiﬁcantly blocked
the eﬀect of EA, demonstrating that the ketanserin dosage-
dependently neutralizes the EA eﬀect by blocking the 5-
HT2A/2C receptors. Previous study shows that the spinal
cord contains abundant 5-HT 2A and 2C receptors [19, 20].
Our data suggest that EA treatment induces the release of
serotonin,whichactivates5-HT2A/2Creceptorsinthespinal
cordtoinhibitpainandincreaseweight-bearingabilityinthe
limb ipsilateral to the injury. This is consistent with previous
studieswhichshowedthati.t.administrationofm-5-HT,a5-
HT2A/2C receptor agonist, dosage-dependently suppressed
the number of ﬂinches in the formalin test and attenuated
thermal hyperalgesia in a rat model of neuropathic pain
[9]. Our data are also in accord with a previous report
that ketanserin at 10μg attenuated the 5-HT-produced anti-
nociceptive eﬀect [21].
In contrast to our study, a previous study demonstrates
that spinal 5-HT1A and 5-HT3 receptor antagonists, but
not the HT2A/2C receptor antagonist ketanserin, blocked
EA-produced inhibition of cold allodynia in a rat model
of neuropathic pain [22]. These data suggest that EA may
involve diﬀerent or multiple mechanisms according to the
nature of the noxious stimulus (e.g., cold allodynia versus
spontaneous pain). However, the involvement of 5-HT1A
and 5-HT3 receptors in EA inhibition of arthritis-induced
pain warrants further study, since an i.t. injection of the 5-
HT3 receptor agonist induced signiﬁcant anti-nociceptive
eﬀects assessed with paw pressure test [21] ,a n da ni . t .
injectionoftheselective5-HT1Areceptorantagonistblocked
the anti-nociceptive action of 5-HT in formalin-induced
pain [23]. Another study demonstrates that EA may activate
serotonin neurons in the nucleus raphe pallidus to modulate
cardiovascular function [24]. In our study, EA activated
serotonergic neurons in the NRM, which sends serotonergic
descending ﬁbers to the spinal cord to modulate pain.
Collectively, these studies suggest that EA activates diﬀerent
areas in the brain that, in turn, modulate various functions.
In summary, this study shows that EA can be used to
activate serotoninergic NRM neurons that project to the
spinal cord, induce spinal serotonin release and stimulate
5-HT2A/2c receptor activities at the spinal cord to inhibit
osteoarthritis-induced pain (Figure 6).
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